Senior lecturer, Department of Biotechnology, Tel-Hai academic collage, Israel & Oxidative Stress and Human Diseases Research Laboratory – Galilee Research.

Slides:



Advertisements
Similar presentations
Parkinson’s Disease (PD)
Advertisements

Parkinson’s Disease Shirley H. Wray, M.D., Ph.D., Professor of Neurology, Harvard Medical School Director, Unit for Neurovisual Disorders Massachusetts.
James Parkinson Born in 1755; died Lived entire life in London. Political reformer Paleontologist Physician.
Movement part 2. Cerebellum and Brainstem KW p. 363.
The Application of the Scientific Method: Preclinical Trials Copyright PEER.tamu.edu.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Parkinson’s Disease First described as the ‘shaking palsy’ by James Parkinson, this neurodegenerative plagues nearly 1 million Americans who have been.
Lewy Bodies in PD. Lewy Body Inclusions and the effect of coffee and decaffeinated extracts on Drosophila neuronal cultures.
What is Aging? Alzheimer’s Disease Parkinson’s Disease.
Abstract Parkinson's disease (PD) is a well known disease estimated to affect 2% of people above age 60. It is a progressively debilitating disease affecting.
V. Neirinckx 1, E. Laudet 1, B. Rogister 1,2,3 and S. Wislet-Gendebien 1. 1 GIGA Neurosciences, University of Liège, Belgium ; 2 GIGA Development, stem.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
By, Blessy Babu. What is Gas Chromatography?  Gas spectroscopy is a technique used to separate volatile components in a mixture.  It is particularly.
Epigenome 1. 2 Background: GWAS Genome-Wide Association Studies 3.
2007 GeneSpring MS GeneSpring for Metabolite BioMarker Analysis using Mass Spectrometry data Agilent Q-TOF VIP Visit Jan 16-17, 2007 Santa Clara, CA Thon.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Subthalamic GAD Gene Therapy in a Parkinson’s Disease Rat Model
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Making Things Happen - 2 Motor Disorders How Your Brain Works - Week 7 Dr. Jan Schnupp HowYourBrainWorks.net.
Oxidative Stress in Skeletal Muscle Diabetes This study was initiated to more rigorously examine insulin actions in the context of heightened state of.
Parkinson’s Disease storyboard. Possible Intro Scenario As an resident at Normal Hospital, you are beginning your rotation in neurology. Your supervisor,
Intranasal Delivery of Proteins Using Cationic Liposomes for the Treatment of Parkinson’s Disease and the Use of Bioquant ® Image Analysis Software Presented.
Parkinson’s Disease superKAT :).
Motor Response Complications and Cycline-Dependent Kinase 5 (Cdk5) Neuroadaptations in an Animal Model of Parkinson’s Disease Heather Minkel Dr. Justin.
PARKINSON’S DISEASE By Courtney and Niral. WHAT IS IT?  Parkinson's disease (PD) is chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s disease – diagnosis in the bowel? David Hilton Department of Cellular and Anatomical Pathology, Derriford Hospital, Plymouth.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN  -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
Metabolomics Metabolome Reflects the State of the Cell, Organ or Organism Change in the metabolome is a direct consequence of protein activity changes.
Temporal Enhancement of Motor Control in Parkinson’s Disease patients Marta Bieńkiewicz PhD Student Queen’s University Belfast.
Dissect the plasma protein markers for Parkinson’s disease Wang Vin-Chi, Lin Ching-Yu, and Chen Han-Min.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
Mitochondria in the etiology and pathogenesis of Parkinson's disease
Improvement of life quality and non motor symptoms relief in patients with advanced Parkinson's disease. Natalia Prican Andra Oltean Doctor Jozsef Attila.
Oregon Health & Science University and Northwest PADRECC
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Anita Mahadevan-Jansen Faraz Ali James Lugge Ernest Moore Mahesh Parlikad.
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital.
Iron accumulation in Patients with Parkinson’s Disease
By Katelyn Chaimson and Sean Guyot
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
Parkinson’s Test Device Development Tiffany Feltman Erin Sikkel.
Pathogenesis and pathology of parkinsonism
Dopaminergic Animal Models of RLS William Ondo, MD Department of Neurology, Baylor College of Medicine Houston, TX
Reflections on animal models of neurological disorders Marie-Francoise Chesselet UCLA
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Anita Mahadevan-Jansen Faraz Ali James Lugge Ernest Moore Mahesh Parlikad.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s Disease.
Modelling Madness Susan Totterdell.
ULTRASONOGRAPHY AND MR IMAGING IN PROGRESSIVE SUPRANUCLEAR PALSY
(vi) AMI+Rotenone H&E X 20
The Effects of 6-hydroxydopamine (6-OHDA) and Neuronal Nitric Oxide Synthase Inhibitor ( nNOSI) on Ability of Zebrafish to recover from parkinson’s disease-like.
Nitric Oxide (NO) and How it Regulates Motor Function
Spes Spirae - A project to make accurate measurements relevant for Parkinson’s disease on a big scale Spesspirae.com
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
III. Parkinson Disease.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Quantitative Detection of Parkinson's Disease Symptoms
PPMI in the Medical Literature
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Drugs for Degenerative Diseases of the Nervous System
Losartan pretreatment reduces neurodegeneration and behavioural symptoms in 6- hydroxydopamine induced unilateral rat model of Parkinson's disease  Ali.
Neurodegenerative diseases
NCS-Rapgef2-dependent ERK activation in mouse NAc following D1 dopamine receptor agonist SKF and psychostimulants D-amphetamine or cocaine administration.
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

Senior lecturer, Department of Biotechnology, Tel-Hai academic collage, Israel & Oxidative Stress and Human Diseases Research Laboratory – Galilee Research Institute (Migal), Israel. Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson’s disease By Dr. Soliman Khatib Oxidative Stress laboratory

Oxidative stress and human diseases laboratory activities Markers Alzheimer, Parkinson, diabetic complications, atherosclerosis, depression Analytical chemistry Isolation, Identification Protein oxidation and modifications Blood Human carotid plaque VOCs as Biomarkers

Parkinson’s disease Parkinson's disease (PD): one of the most prevalent neurodegenerative disorders Affecting : 0.3% of the entire population, 1% of the people over 65yr, 4% of the people over 80yr.

Parkinson’s Disease (PD) Pathology Pathology is characterized with the death of dopaminergic neurons in the substantia nigra Para compacta and a reduction in dopamine (DA) levels in the striatum and the presence of “Lewy Bodies”.

Symptoms of PD Tremor Rigidity Bradykinesia Postural instability

loss of 50-70% of Dopaminrgic neurons 80% reduction in the striatal dopamine Parkinson’s disease and dopamine

Early detection of PD Early detection of PD is important as it enables slowing or stopping its progression using neuroprotective drugs. Although there are several biomarkers for clinical diagnosis, none of these is in routine clinical use. Thus, a need for an early, reliable, sensitive and specific diagnostic biomarker still exits.

Aim of the study Early detection of PD

PD 9 Volatile organic compounds (VOCs) in blood Early detection of PD stage and progression Biochemical pathways specific to the disease Hypothesis

Objectives 1. To identify VOCs in rates blood that can be specific to Parkinson disease. To investigate the mechanism of such specific VOCs generation and their association with the disease.

VOCs can be detected by using the simple and reliable Solid-Phase Micro Extraction (SPME) technique, combined with Gas-Chromatography Mass Spectrometry (GC-MS). SPME Method

1. Fiber type: (DVB/CAR/PDMS) (gray fiber) or (PDMS) (red fiber). Optimization of the SPME method 2. SPME Extraction Temperature ( 40C Vs 90C) 3. Blood or Serum Gray fiber Red fiber 40 0 C 90 0 C Blood Serum

The requirement for the algorithm In each experiment – numerous GC-MS peaks Each chromatogram contains hundreds of peaks The need for an automatic and reliable algorithm for data handling, signal processing and analysis 13

Development of an algorithm for data handling and processing. accurately detecting and demarcating the peaks in the GC-MS chromatogram. calculating the area under each detected peak eliminating peaks originated from blanks, Normalization of the area under each peak using internal standards finding and selecting sample peaks with areas significantly higher or lower than in control.

Baseline computation and removal 15

“Peak picking” Selecting peaks: peak-to-noise ratio>3dB Left and right boundaries 16 Peak detection and boundary demarcation

Peaks alignment and grouping Aim: targeting peaks partial GC/MS signals from 5 different samples, each contains several local maxima, aligned on a common time-scale. The retention times of peaks which stem from the same compound are shown for all samples, demonstrating the small shifts between different samples.

Area computation and Internal Standard Correction Interpolation Win= 5 Time Alignment & Clustering k Area Computation Low-pass Filtering win= 50 Area Computation Outlier Selection Sample peaks Baseline signal 1 N 2 Internal Standard Areas Blank peaks 18

Area versus retention-time of all peaks in all blood samples. Dotted red lines represent peaks originated from blanks, and solid blue lines represent peaks where no blanks were present. Peaks vs. Blanks

Rat model: Stable- 50% depletion of dopaminergic neurons by injection of 6-OHDA i.c.v into the left lateral ventricle (Aluf et al. FRR, 2010). SHAM 125µg 6-OHDA 250 µg 6-OHDA 325 µg 6-OHDA (**P<0.01, one way ANOVA, n = 7) PD Rates model

Method 1- Rates were injected by i.c.v into the left lateral ventricle with 250  g 6-OHDA, or i.p injection of (DSP-4), 50 mg/kg or seline. 2- after 5 weeks blood was collected. 3- rats were decapitated, the brain removed and the striatum dissected, weighted and homogenized into PBS. 4- dopamine content in striatum determined using HPLC connected to ECD. 5- VOCs from Blood and striatum homogenate were determined using SPME-GC-MS method PBS was used as blank. 6- data processed and analyzed using the developed algorithm.

Dopamine levels in the striatum homogenate of rats DA= Dopamine HDA= 6-hydroxydopamine (HDA) DSP-4= N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine

The level of VOCs in treated versus control rats as analyzed by SPME/GC-MS. A: Blood B: Brain homogenate

The MS fragmentations of peaks spectra of 1-Octen-3-ol from blood spectra of 1-Octen-3-ol from standard spectra of 2-Ethylhexanol from blood spectra of 2-Ethylhexanol from standard

VOCs detected in blood or Brain Homogenate

1-Octen-3-ol is neurotoxic in the Drosophila melanogaster model and to human embryonic stem cells. (Inamdar et al Neurotox Res 2014) it reduces dopamine levels, causes dopamine neuron degeneration. (Inamdar et al. PNAS, 2013;) 1-Octen-3-ol has been detected in cow milk (van Aardt et al., 2005), human sweat (Cork and Park, 1996), and feces (Garner et al., 2007).

Summary Three groups of rats were studied: DA-lesioned rats injected with 6-hydroxydopamine ( n=11); control rats injected with saline (n=9); and control rats injected with DSP-4 (n=8), a specific noradrenergic neuron toxin. The SPME method was optimized for testing Blood VOCs An algorithm for data processing was developed In the blood, 1-octen-3-ol and 2-ethylhexanol were found at significantly higher concentrations in HDA-treated versus sham rats.

Summary In the striatal homogenate 1-octen-3-ol and other four compounds were found at significantly lower concentrations in HDA rate

Future plans To examine the presence of volatile materials in Parkinson human blood. To investigate the mechanism of the obtained VOCs generation and their association with the disease.

III. Novel markers for extra cellular OS 2. Extra cellular OS: Microdialysis of a non dialyzable marker (ROS/RNS trap). Inlet Outlet

Oxidative stress- extra cellular marker oxidation Increased oxidative stress is observed in our rat model (44% and 28% increase in the level of oxidized products of the marker), NAC decreased the increment almost back to normal (n=5/6 rats per treatment; ***p<0.001, **p<0.01, *p<0.05)

Thanks Prof. Jacob Vaya. Dr. Soliman Khatib. Saeed Mahmoud and our group. Prof. John Finberg Dr. Yuval Aluf. Dr. Yizhar Lavner.